ReviewLeukemia2009
The complete evaluation of erythrocytosis: congenital and acquired.
Review in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 127 citations in OpenAlex.
- Familial erythrocytosis associated with anBMJ case reports · 2026Article
- The Overlooked Diagnosis: Unraveling a Case of Gaisböck Syndrome.Annals of African medicine · 2026Article
- Etiology, Diagnosis, and Genetic Analysis of Polycythemia in Pediatric Population.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Two Novel Genetic Variants Involved in the Oxygen Sensing Pathway in JAK2-unmutated Erythrocytosis.Biochemical genetics · 2025Article
- Redefining chronic mountain sickness: insights from high-altitude research and clinical experience.Medical review (2021) · 2025Review
- Case Report: Importance of high-throughput genetic investigations in the differential diagnosis of unexplained erythrocytosis.Pathology oncology research : POR · 2025Article
- Effect of smoking and smoking cessation on hematological parameters in polycythemic patients.Open medicine (Warsaw, Poland) · 2025Article
- Diagnostic Performance of Serum Erythropoietin to Discriminate Polycythemia Vera from Secondary Erythrocytosis through Established Subnormal Limits.Diagnostics (Basel, Switzerland) · 2024Article
- Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.Frontiers in pharmacology · 2024Article
- Secondary Polycythemia May Be an Early Clinical Manifestation of Multiple Myeloma: A Case Report.Journal of blood medicine · 2024Article
- TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model.Frontiers in oncology · 2024Article
- Article
- One gene, two opposite phenotypes: a case report of hereditary anemia due to a loss-of-function variant in theHaematologica · 2023Article
- Variants in the new E1' cryptic exon of theEJHaem · 2022Article
- Undiagnosed polycythemia, an uncommon cause of Wallenberg syndrome: A case report.Clinical case reports · 2022Article
- Clinical Characteristics of Pediatric Patients with Congenital Erythrocytosis: A Single-Center Study.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis.Scientific reports · 2022Article
- Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approach to a patient with erythrocytosis is greatly simplified by assessing the clonality of the process upfront. In this regard, there has been a dramatic shift toward genetic testing and away from traditional tests, such as measurement of red cell mass. Clonal erythrocytosis is the diagnostic feature of polycythemia vera (PV) and is almost always associated with a JAK2 mutation (JAK2V617F or exon 12). All other scenarios represent non-clonal erythrocytosis, often referred to as secondary erythrocytosis. Serum erythropoietin (Epo) level is usually normal or elevated in secondary erythrocytosis and subnormal in PV. Therefore, in a patient with acquired erythrocytosis, it is reasonable to begin the diagnostic work-up with peripheral blood JAK2 mutation analysis and serum Epo measurement to distinguish PV from secondary erythrocytosis. Conversely, the patient with life-long erythrocytosis is more likely to suffer from congenital polycythemia and should therefore be evaluated for germline mutations that result in enhanced Epo effect (for example, Epo receptor mutations), altered intracellular oxygen sensing (for example, mutations involving the von Hippel-Lindau tumor suppressor gene) or decreased P50 (for example, high-oxygen-affinity hemoglobinopathy). The order of tests in this instance depends on the clinical scenario and serum Epo level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.